OUR PURPOSE PIONEERING SCIENCE 118 2021 ESG MATERIALITY ASSESSMENT BIOGEN 2021 YEAR IN REVIEW PATIENTS OUR PEOPLE ENVIRONMENT COMMUNITY REPORTING Analyzing the data Our multi-phase analysis included a rank ordering of issues and a review of open-text responses. We combined responses with similar meanings but different wording (e.g., “talent” and “employees”) to uncover patterns in the data. Since combining all stakeholder responses could be misleading, we calculated the average for each stakeholder group and also combined group averages to create a variety of actionable data views. Among other things, we evaluated: – Internal versus external perspectives: We considered whether external stakeholders and employees see Biogen differently, and which audiences hold the highest expectations of us – and on which issues. – Themes by stakeholder group: We looked for significant similarities and differences in how each category of stakeholders sees priority issues. For example, we considered whether investors and suppliers expect different things from Biogen than NGOs or researchers do. – Issue importance vs. performance: By comparing issue importance to stakeholder views of both Biogen’s current and expected performance, we were able to determine whether any gaps were the result of high expectations, low perceptions of performance, or both. Sharing key findings Our analysis found that the relative priority order of issues was largely similar across stakeholders, with internal and external stakeholders agreeing on eight of their top 10 issues. This exercise also uncovered some important shifts. Compared to our last ESG materiality assessment, five of the top 10 issues remained constant, and five new issues entered the top 10. Among the issues that grew in importance are bioethics; workplace/employee health & safety; talent recruitment, retention and engagement; pharmaceuticals in the environment; and health equity. Stakeholder input leads us to see these changes as driven by the ongoing COVID-19 pandemic and the “Great Resignation,” heightened environmental concerns, and the renewed social justice movement. Acting on material ESG issues BUILDING ON BIOGEN’S MANY STRENGTHS Stakeholders perceive key material issues and Biogen strengths as including Our progress Community Engagement & Foundation Giving Biogen and the Biogen Foundation contributed more than $80 million in grants, sponsorships and in-kind contributions in 2021, and this year will celebrate the Foundation’s 20 th anniversary. Þ LEARN MORE Economic Performance With 2021 revenues of $10,982 million, Biogen was #1 in our industry on the JUST 100 for capital management. Þ LEARN MORE Climate Climate is an area where Biogen significantly exceeds expectations. In 2020, Biogen became the first Fortune 500 company to commit to going beyond net zero to achieve 100% fossil fuel free operations by 2040. Þ LEARN MORE Diversity, Equity & Inclusion/ Racial Justice With 47.6% of director and above positions held by women globally and 26% held by minorities in the U.S. in 2021, we are advancing our 4-part DE&I strategy both internally and externally. Þ LEARN MORE R&D, Pipeline & Innovation 94% of stakeholders surveyed see Biogen as a pioneer in neuroscience. Biogen is working to strengthen our culture of innovation, enhance our strategic portfolio and advance our pipeline of therapies. Þ LEARN MORE ADDRESSING KEY OPPORTUNITIES FOR CONTINUOUS IMPROVEMENT Stakeholders perceive key material issues and opportunities for continuous improvement as including Our progress Access & Pricing Biogen is committed to patient access and transparency in our programs and pricing. Þ LEARN MORE Recruitment, Talent Retention & Engagement In a tight labor market, we are actively advancing programs that spark even deeper engagement and enable all employees to thrive at Biogen. Þ LEARN MORE Health Equity Biogen is committed to health equity and access, including clear goals that are part of our 4-part DE&I strategy. Þ LEARN MORE Health System Strengthening From our work with Harvard University to help under-resourced health clinics address climate risks to donations of medical supplies to issue advocacy, Biogen is actively engaged in a wide range of programs to help strengthen health systems around the world. Þ LEARN MORE IN THE PATIENTS AND COMMUNITY SECTIONS OF THIS REPORT Bioethics Biogen is advancing responsible product development, which begins in the earliest stages of R&D, with clear guidelines on issues such as bioethics. Þ READ ABOUT OUR PRINCIPLES, POLICIES AND POSITIONS